AkatG315 Mutation Alone Should Not Lead to Exclusion of Isoniazid in Treatment of Multidrug-Resistant Tuberculosis

European Respiratory Journal- United Kingdom

doi 10.1183/13993003.01696-2017

Full Text

Abstract

Available in

Date

Authors

Publisher

European Respiratory Society (ERS)

Related search

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis

InPharma
1988English

Reducing Harm in the Treatment of Multidrug-Resistant Tuberculosis

The Lancet
Medicine
2018English

Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Genome and MIC Stability in Mycobacterium Tuberculosis and Indications for Continuation of Use of Isoniazid in Multidrug-Resistant Tuberculosis

Journal of Medical Microbiology
MedicineMicrobiology
1997English

Multidrug Resistant Tuberculosis

British Medical Journal
Medicine
2015English

Recurrence After Successful Treatment of Multidrug-Resistant Tuberculosis in Taiwan

PLoS ONE
Multidisciplinary
2017English

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis

RUHS Journal of Health Science
2019English

Revolutionary New Treatment Regimens for Multidrug-Resistant Tuberculosis

The Lancet Infectious Diseases
Infectious Diseases
2019English

Shorter Regimens for Multidrug-Resistant Tuberculosis Should Also Be Applicable in Europe

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy